A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept

Autor: Stan J. F. Hartman, Joost G. E. Swaving, Stijn W. van Beek, Bianca D. van Groen, Marika de Hoop, Tjitske M. van der Zanden, Rob ter Heine, Saskia N. de Wildt

Publikováno v: Frontiers in Pharmacology, Vol 11 (2020)

Background: Modeling and simulation is increasingly used to study pediatric pharmacokinetics, but clinical implementation of age-appropriate doses lags behind. Therefore, we aimed to develop model-informed doses using published pharmacokinetic data a

Externí odkaz: https://doaj.org/article/afbf1afcd27242b68dc6c6e9d324dabe

Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature

Autor: Saskia N. de Wildt, Roger J. M. Brüggemann, L Orriëns, Stan J. F. Hartman, Michiel F. Schreuder, Nada Dia

Publikováno v: Clinical Pharmacokinetics, 59(2), 173-205. Adis
Clinical Pharmacokinetics, 59, 2, pp. 173-205
Clinical Pharmacokinetics, 59, 173-205
Clinical Pharmacokinetics

Background Pharmacokinetics (PK) are severely altered in critically ill patients due to changes in volume of distribution (Vd) and/or drug clearance (Cl). This affects the target attainment of antibiotics in critically ill children. We aimed to ident

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5496fa546028d628563b28e25644be2
https://doi.org/10.1007/s40262-019-00813-w

Proenkephalin as a new biomarker for pediatric acute kidney injury - reference values and performance in children under one year of age

Autor: Joost van Rosmalen, Nadies E C van de Water, Michiel F. Schreuder, Dick Tibboel, Saskia N. de Wildt, Stan J. F. Hartman, Oliver Hartmann, Joachim Struck, Janin Schulte, Remi Beunders, Peter Pickkers, Alexandra J M Zwiers

Publikováno v: Clinical Chemistry and Laboratory Medicine, 58(11), 1911-1919. De Gruyter
Clinical Chemistry and Laboratory Medicine, 58, 11, pp. 1911-1919
Clinical Chemistry and Laboratory Medicine, 58, 1911-1919

Objectives Acute kidney injury (AKI) is common in critically ill children, but current biomarkers are suboptimal. Proenkephalin A 119–159 (PENK) is a promising new biomarker for AKI in adults, but pediatric data is lacking. We determined PENK refer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bf6e0a888c3bb55af8a231be42f450
https://doi.org/10.1515/cclm-2020-0381

Ornithopod and Sauropod Dinosaur Remains from the Maastrichtian Al-Khod Conglomerate, Sultanate of Oman

Autor: Ann S. Schulp, Patrick M.O'Connor, David B. Weishampel, Abdul Razak Al Sayigh, Abdulrahman Al-Harthy, John W.M. Jagt, Axel F. Hartman

Publikováno v: Sultan Qaboos University Journal for Science, Vol 13, Iss 0, Pp 27-32 (2008)

Fieldwork in the Upper Cretaceous (Maastrichtian) Al-Khod Conglomerates in the Sultanate of Oman led to the discovery of a large bone fragment tentatively identified as a partial distal left humerus of a sauropod and an ornithopod dorsal vertebra. Th

Externí odkaz: https://doaj.org/article/3534a0816f1c4664ab2e528e4191047d

The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study

Autor: Stan J. F. Hartman, Catherijne A. J. Knibbe, Joost van Rosmalen, Bianca D van Groen, Saskia N. de Wildt, N. Harry Hendrikse, Karel Allegaert, Birgit C. P. Koch, Dick Tibboel, Albert D. Windhorst, Elke H. J. Krekels, Esther van Duijn, Miriam G. Mooij, Wouter H. J. Vaes

Publikováno v: Clinical Pharmacology and Therapeutics, 109(1), 140-149. Wiley-Blackwell
Clinical Pharmacology and Therapeutics, Epub 13 May
Clinical Pharmacology and Therapeutics, 109, 140-149
van Groen, B D, Krekels, E H J, Mooij, M G, van Duijn, E, Vaes, W H J, Windhorst, A D, van Rosmalen, J, Hartman, S J F, Hendrikse, N H, Koch, B C P, Allegaert, K, Tibboel, D, Knibbe, C A J & de Wildt, S N 2021, ' The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study ', Clinical Pharmacology and Therapeutics, vol. 109, no. 1, pp. 140-149 . https://doi.org/10.1002/cpt.1890, https://doi.org/10.1002/cpt.1890
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 109, 1, pp. 140-149

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug-metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to children, yet knowledge is lacking on the oral bioavailability in term neon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b91723dc49e8ea4eb1c1336430edfbb
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/232102